Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.54 |
| ▸ | CLK1 | P49759 | 9/20 | 0.51 |
| ▸ | CLK2 | P49760 | 9/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.51 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | CCND3 | P30281 | 2/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25736247 | 0.93 | CDK1 (0.55) | CDK1CLK1CLK2CLK4CDK4 | |
| SCHEMBL25736244 | 0.93 | CDK1 (0.52) | CDK1CLK1CLK2CLK4CDK4 | |
| SCHEMBL20550112 | 0.92 | CDK5 (0.56) | CDK1CLK1CLK2CLK4CDK4 | |
| SCHEMBL20550113 | 0.92 | CDK5 (0.56) | CDK1CLK1CLK2CLK4CDK4 | |
| SCHEMBL25737225 | 0.90 | CDK1 (0.59) | CDK1CLK1CLK2CLK4CDK4 | |
| SCHEMBL21472915 | 0.87 | CDK5 (0.61) | CDK1CLK1CLK2CLK4CDK4 | |
| SCHEMBL18113885 | 0.84 | CDK5 (0.47) | CDK1CDK4CCNB1CDK5CDK5R1 | |
| SCHEMBL25736248 | 0.83 | CDK1 (0.61) | CDK1CLK1CLK2CLK4CDK4 | |
| SCHEMBL25736246 | 0.83 | CDK1 (0.59) | CDK1CLK1CLK2CLK4CDK4 | |
| SCHEMBL6775420 | 0.82 | CCNE2 (0.63) | CDK1CDK2CCNE2CCNA2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK1 3/4885CLK1 338/4885CLK2 176/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK1 3/4885CLK1 338/4885CLK2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.